Article

Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials

2022-01-13

Abstract excerpt

<h4>Background: </h4> Patients with severe hemophilia often present with painful joint and soft tissue bleeding which may restrict them from their daily activities. The current standard of care still relies on a regular prophylactic factor VIII (FVIII), which has a high daily treatment burden. Recently, rurioctocog alfa pegol, a third-generation recombinant FVIII with a modification in its polyethylene glycol (PEG...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 889fc0a9-e930-56c0-ac0c-26d29e153252
DOI: 10.12688/f1000research.73884.3

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trialsDOI 10.12688/f1000research.73884.3Read

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia ASemantic proximity Read

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Semantic proximity Read

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialSemantic proximity Read

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and ChallengesSemantic proximity Read

Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspectiveSemantic proximity Read

Key insights to understand the immunogenicity of FVIII products.Semantic proximity Read

Recent Advances in the Treatment of Hemophilia: A ReviewSemantic proximity Read

Prophylactic Therapy with Emicizumab in Patients with Hemophilia A: Benefits and ChallengesSemantic proximity Read

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.Semantic proximity Read

Biological considerations of plasma-derived and recombinant factor VIII immunogenicitySemantic proximity Read

The long and short of it: using the new factor products.Semantic proximity Read

Navigation of the Hemophilia Drug Choice-Paralysis: A Quick User Guide to New and Existing TherapiesSemantic proximity Read